Jonathan Zalevsky - Net Worth and Insider Trading
Jonathan Zalevsky Net Worth
The estimated net worth of Jonathan Zalevsky is at least $450,923 dollars as of 2024-05-21. Jonathan Zalevsky is the Chief R&D Officer of Nektar Therapeutics and owns about 257,670 shares of Nektar Therapeutics (NKTR) stock worth over $450,923. Details can be seen in Jonathan Zalevsky's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jonathan Zalevsky has not made any transactions after 2024-05-17 and currently still holds the listed stock(s).
Transaction Summary of Jonathan Zalevsky
Jonathan Zalevsky Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Jonathan Zalevsky owns 1 companies in total, including Nektar Therapeutics (NKTR) .
Click here to see the complete history of Jonathan Zalevsky’s form 4 insider trades.
Insider Ownership Summary of Jonathan Zalevsky
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NKTR | Nektar Therapeutics | 2024-02-20 | Chief R&D Officer |
Jonathan Zalevsky Latest Holdings Summary
Jonathan Zalevsky currently owns a total of 1 stock. Jonathan Zalevsky owns 257,670 shares of Nektar Therapeutics (NKTR) as of May 17, 2024, with a value of $450,923.
Latest Holdings of Jonathan Zalevsky
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NKTR | Nektar Therapeutics | 2024-05-17 | 257,670 | 1.75 | 450,923 |
Holding Weightings of Jonathan Zalevsky
Jonathan Zalevsky Form 4 Trading Tracker
According to the SEC Form 4 filings, Jonathan Zalevsky has made a total of 21 transactions in Nektar Therapeutics (NKTR) over the past 5 years, including 0 buys and 21 sells. The most-recent trade in Nektar Therapeutics is the sale of 7,355 shares on May 17, 2024, which brought Jonathan Zalevsky around $12,871.
Insider Trading History of Jonathan Zalevsky
- 1
Jonathan Zalevsky Trading Performance
Jonathan Zalevsky Ownership Network
Jonathan Zalevsky Owned Company Details
What does Nektar Therapeutics do?
Who are the key executives at Nektar Therapeutics?
Jonathan Zalevsky is the Chief R&D Officer of Nektar Therapeutics. Other key executives at Nektar Therapeutics include SVP & General Counsel Mark Andrew Wilson , director & President & CEO Howard W Robin , and Chief Financial Officer Sandra A. Gardiner .
Nektar Therapeutics (NKTR) Insider Trades Summary
Over the past 18 months, Jonathan Zalevsky made 6 insider transaction in Nektar Therapeutics (NKTR) with a net sale of 55,993. Other recent insider transactions involving Nektar Therapeutics (NKTR) include a net sale of 116,554 shares made by Howard W Robin , a net sale of 44,084 shares made by Mark Andrew Wilson , and a net sale of 56,000 shares made by .
In summary, during the past 3 months, insiders sold 86,265 shares of Nektar Therapeutics (NKTR) in total and bought 0 shares, with a net sale of 86,265 shares. During the past 18 months, 291,616 shares of Nektar Therapeutics (NKTR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 291,616 shares.
Nektar Therapeutics (NKTR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Nektar Therapeutics Insider Transactions
Jonathan Zalevsky Mailing Address
Above is the net worth, insider trading, and ownership report for Jonathan Zalevsky. You might contact Jonathan Zalevsky via mailing address: 455 Mission Bay Boulevard South, C/o Nektar Therapeutics, San Francisco Ca 94158.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
